Sr. Director - IBU Consumer Media at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, PharmaceuticalsIndustries

Requirements

Global leadership with strategic vision and operational rigor
Ability to influence across geographies, cultures, and functions
In-market experience outside the U.S. combined with deep understanding of U.S. standards, priorities, and performance expectations
Enterprise mindset: Balances global priorities with regional realities and adapts to diverse cultural/regulatory environments
Influence through partnership: Acts as connector/unifier across stakeholders, geographies, and functions
Operational excellence: Establishes frameworks, standards, and tools to simplify complexity and scale impact
Curiosity and adaptability: Anticipates evolving market, media, and cultural dynamics
Empowerment: Strengthens affiliate capabilities through guidance, mentorship, and collaboration
Experience operating through influence with cross-functional stakeholders, agencies, and regional leaders (minimal direct reports)

Responsibilities

Lead Disease State Education (DSE) paid media strategy, governance, and communication planning across Lilly’s International Business Units (IBUs), focusing on disease state campaigns and key affiliates/major hubs
Serve as central connection point between global strategy and local activation, ensuring alignment to enterprise priorities, investment optimization, and operational excellence
Partner closely with IBU brand, analytics, and affiliate leadership, as well as Publicis and local agency teams
Establish frameworks, operating models, and best practices to enable affiliates to drive efficient investment and quality execution
Define overarching paid media framework for disease state and priority brand campaigns across key affiliates and major hubs, aligning with enterprise objectives while enabling local flexibility
Lead development of global communication planning framework
Act as key bridge between Lilly’s Global Media team and IBU markets, translating global direction into locally relevant action
Guide large network of cross-functional and in-market stakeholders toward unified vision for media excellence

Skills

Paid Media Strategy

Disease State Education

Media Governance

Communication Planning

Global Strategy

Local Activation

Operating Models

Best Practices

Analytics

Agency Management

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free